A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT02565511 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimers Disease

Interventions

BIOLOGICAL: CAD106 Immunotherapy
OTHER: Placebo to CAD106
DRUG: CNP520
OTHER: Placebo to CNP520
OTHER: Alum

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]
[object Object]
[object Object]